Lonza Group AG (LONN)

Switzerland
Currency in CHF
539.20
-2.40(-0.44%)
Closed·
LONN Scorecard
Full Analysis
Management has been aggressively buying back shares
Earnings results expected today
Fair Value
Day's Range
532.80542.80
52 wk Range
467.80616.00
Key Statistics
Edit
Bid/Ask
530.00 / 540.00
Prev. Close
539.2
Open
538.6
Day's Range
532.8-542.8
52 wk Range
467.8-616
Volume
196.41K
Average Vol. (3m)
187.37K
1-Year Change
7.24%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LONN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
654.89
Upside
+21.46%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple
Show more

Lonza Group AG Company Profile

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics; Small Molecules; Cell & Gene; and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. Its Small Molecules segment provides integrated development and manufacturing services for small molecule drug substances and their intermediates. This segment also supports customers across aspects of design, development, and manufacturing, such as particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. Its Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.

Compare LONN to Peers and Sector

Metrics to compare
LONN
Peers
Sector
Relationship
P/E Ratio
59.9x20.3x−0.5x
PEG Ratio
-−0.060.00
Price / Book
4.1x2.6x2.6x
Price / LTM Sales
5.8x3.8x2.9x
Upside (Analyst Target)
20.5%63.1%60.8%
Fair Value Upside
Unlock39.1%10.8%Unlock

Analyst Ratings

18 Buy
5 Hold
0 Sell
Ratings:
23 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 654.89
(+21.46% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 8.94%
Dividend Yield
0.74%
Industry Median 1.22%
Annualized Payout
4.00
Paid unevenly
5-Years Growth
+7.78%
Growth Streak

Earnings

Latest Release
Feb 11, 2025
EPS / Forecast
-- / 10.40
Revenue / Forecast
-- / 3.385B
EPS Revisions
Last 90 days

People Also Watch

195.55
SIKA
-0.23%
87.62
HOLN
-0.88%
141.80
SRENH
+1.18%
1,058.00
PGHN
+0.19%

FAQ

What Is the Lonza Group (LONN) Stock Price Today?

The Lonza Group stock price today is 539.20

What Stock Exchange Does Lonza Group Trade On?

Lonza Group is listed and trades on the Switzerland stock exchange.

What Is the Stock Symbol for Lonza Group?

The stock symbol for Lonza Group is "LONN."

Does Lonza Group Pay Dividends? What’s The Current Dividend Yield?

The Lonza Group dividend yield is 0.74%.

What Is the Lonza Group Market Cap?

As of today, Lonza Group market cap is 37.96B.

What is Lonza Group Earnings Per Share?

The Lonza Group EPS is 8.94.

What Is the Next Lonza Group Earnings Date?

Lonza Group will release its next earnings report on Apr 22, 2025.

From a Technical Analysis Perspective, Is LONN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.